What peptides are best for weight loss?

The only peptides with strong randomized evidence for weight loss are the GLP-1 receptor agonists, which are FDA-approved prescription drugs that happen to be peptides. Among research-channel peptides (AOD-9604, the GH secretagogues, MOTS-c), none has solid human weight-loss trial data, and AOD-9604 actually failed its obesity trial. The effective option is a prescription, not a research vial.

Does AOD-9604 burn fat?

Its own clinical program says no. AOD-9604, a growth-hormone fragment, was tested for obesity and the key Phase 2b trial did not beat placebo, after which development for weight loss stopped. It is still sold as a fat-loss research peptide on a claim its trials failed to support. See our AOD-9604 review for the full evidence ledger.

Are weight-loss peptides safe?

The approved GLP-1 drugs have known, labeled safety profiles and medical supervision. Research-channel weight-loss peptides are a different question entirely: unverified identity, purity and dose, no monitoring, and in the case of GH secretagogues, real hormonal effects (insulin resistance, fluid retention) on top of the supply risk. We do not link to any vendor, and self-dosing an unregulated metabolic peptide is a genuine risk. More in are peptides safe.

Can collagen peptides help with weight loss?

Not directly. Collagen has no weight-loss evidence. Its one body-composition result paired 15 g daily with resistance training in older adults and improved fat-free mass, a muscle effect, not fat loss, and it is a poor-quality protein for that purpose besides. If you want collagen for its actual evidence (skin, joints), our collagen peptides review covers it.

Why doesn't PepVise sell or link to weight-loss peptides?

Because the only ones that work are prescription drugs that belong in a clinical channel, and the rest are sold on claims their trials never supported. Linking to grey-market vials of either would be a site-ending breach of our affiliate boundary. We grade the science and route you to a clinician for the drugs that actually have the evidence.

Compound profile· Evidence

Peptides for weight loss, graded by evidence

By The PepVise Editorial Team · Reviewed June 4, 2026 · 12 min read

One peptide class genuinely drives weight loss in trials. The rest, sold as fat-loss peptides in the research-chemical channel, range from weakly supported to abandoned. An honest map of both.

We describe what has been measured — by whom, at what scale, with what effect size, and with what caveats. Hedging, here, is honesty.

— The PepVise Editorial Teamfrom the house style guide

Methodology

How we read the literature

Evidence tier: We grade the literature on four tiers, High (replicated RCTs or meta-analyses), Moderate (multiple trials with mixed findings), Low (a single pilot or case series), and Anecdotal (preclinical only, no human data). The tier appears on every compound profile beside the claim it supports.
Trial stage: Where a compound sits in the human development pipeline is recorded as Preclinical, Phase 1, Phase 2, or Phase 3+. We pull the current stage from ClinicalTrials.gov and the EU Clinical Trials Register on access date and re-verify quarterly.
Regulatory status: We state the FDA posture plainly, approved for indication X, or labeled for research use only, or removed from the 503A list, or investigational under a specific IND. Regulatory status changes; every post carries a review date.
Where we're uncertain: Every compound profile closes with a named uncertainty section, the question we can't answer from the current literature, the trial we'd want to see, the effect size we'd treat as a real signal. Uncertainty is not a failure mode here; it's load-bearing.

Frequently asked

The questions readers actually bring us.

What peptides are best for weight loss?: The only peptides with strong randomized evidence for weight loss are the GLP-1 receptor agonists, which are FDA-approved prescription drugs that happen to be peptides. Among research-channel peptides (AOD-9604, the GH secretagogues, MOTS-c), none has solid human weight-loss trial data, and AOD-9604 actually failed its obesity trial. The effective option is a prescription, not a research vial.
Does AOD-9604 burn fat?: Its own clinical program says no. AOD-9604, a growth-hormone fragment, was tested for obesity and the key Phase 2b trial did not beat placebo, after which development for weight loss stopped. It is still sold as a fat-loss research peptide on a claim its trials failed to support. See our AOD-9604 review for the full evidence ledger.
Are weight-loss peptides safe?: The approved GLP-1 drugs have known, labeled safety profiles and medical supervision. Research-channel weight-loss peptides are a different question entirely: unverified identity, purity and dose, no monitoring, and in the case of GH secretagogues, real hormonal effects (insulin resistance, fluid retention) on top of the supply risk. We do not link to any vendor, and self-dosing an unregulated metabolic peptide is a genuine risk. More in are peptides safe.
Can collagen peptides help with weight loss?: Not directly. Collagen has no weight-loss evidence. Its one body-composition result paired 15 g daily with resistance training in older adults and improved fat-free mass, a muscle effect, not fat loss, and it is a poor-quality protein for that purpose besides. If you want collagen for its actual evidence (skin, joints), our collagen peptides review covers it.
Why doesn't PepVise sell or link to weight-loss peptides?: Because the only ones that work are prescription drugs that belong in a clinical channel, and the rest are sold on claims their trials never supported. Linking to grey-market vials of either would be a site-ending breach of our affiliate boundary. We grade the science and route you to a clinician for the drugs that actually have the evidence.

What would change our reading

A Phase 2 randomized trial with blinded outcome assessment would change the reading. A new independent replication outside the currently dominant research group would change the reading. A regulatory action — approval, restriction, or a class warning — would change the reading. When any of those lands, we update this profile within a week and mark what changed.

The sources

References cited on this page.

PubMed, ClinicalTrials.gov, and FDA documents only. Secondary sources appear when needed to characterize public discourse, never as a source for a clinical claim.

The masthead

About The Pepvise Editorial Team

The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.

Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →

Adjacent in the literature.

Evidence · Explainer

BPC-157 for Tendon Repair, Literature Review

Inclusion criteria, 8-10 preclinical studies tabulated, the human evidence gap, and an honest assessment of the tendon claims.

12 min read

Evidence · Compound profile

Peptides for Muscle Growth: The Evidence, Graded

Growth-hormone secretagogues, IGF-1 peptides and collagen all get sold for muscle. What the human trials actually show, why GH peptides disappoint lifters, and the legal options that beat all of them.

11 min read

Get the 2026 Peptide Evidence Ledger.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.